VIR BIOTECHNOLOGY, INC. (VIR): Price and Financial Metrics
VIR Price/Volume Stats
| Current price | $8.04 | 52-week high | $27.48 |
| Prev. close | $8.13 | 52-week low | $7.72 |
| Day low | $8.02 | Volume | 767,400 |
| Day high | $8.29 | Avg. volume | 1,039,699 |
| 50-day MA | $10.00 | Dividend yield | N/A |
| 200-day MA | $10.69 | Market Cap | 1.08B |
VIR Stock Price Chart Interactive Chart >
VIR BIOTECHNOLOGY, INC. (VIR) Company Bio
Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA.
Latest VIR News From Around the Web
Below are the latest news stories about VIR BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate VIR as an investment opportunity.
I See a Good Trade on a $10 Biotech StockSmall biotech Vir Biotechnology, Inc. took a bit of a dump lower in July when its mid-stage flu candidate posted disappointing trial results. This is because as of the end of the third quarter, VIR Biotechnology had net cash of $1.7 billion. This means an investor is essentially getting VIR's assets for free and this can be mitigated even further via a covered call strategy. |
Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value CreationSAN FRANCISCO, December 13, 2023--Vir Biotechnology makes strategic changes to focus capital allocation on programs with the highest potential for patient impact and value creation. |
Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare ConferenceSAN FRANCISCO, December 06, 2023--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer, will present at the J.P. Morgan 2024 42nd Annual Healthcare Conference on Wednesday, January 10, at 3:45 p.m. PT / 6:45 p.m. ET. |
7 Small-Cap Stocks to Buy BEFORE the Year-End Rallyexplore and wager on these top small-cap stocks to buy, poised for significant gains in today's dynamic global economy |
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023SAN FRANCISCO, November 13, 2023--Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023 |
VIR Price Returns
| 1-mo | -19.36% |
| 3-mo | -15.81% |
| 6-mo | 3.61% |
| 1-year | -67.12% |
| 3-year | -84.24% |
| 5-year | N/A |
| YTD | -20.08% |
| 2023 | -60.25% |
| 2022 | -39.55% |
| 2021 | 56.35% |
| 2020 | 112.96% |
| 2019 | N/A |
Loading social stream, please wait...